HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis
Peripheral neuropathy in HIV: prevalence and risk factors
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection
Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV–hepatitis C virus co-infection
Trends in unsafe sex and influence of viral load among patients followed since primary HIV infection, 2000–2009
Ignoring the group in group-level HIV/AIDS intervention trials: a review of reported design and analytic methods
Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants
The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients
Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?
The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score
Reply to comment on ‘pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’
Reply to ‘Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’
New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B
Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents